Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 21, 2021

BeiGene’s Brukinsa receives approval to treat mantle cell lymphoma in Russia

The Russia Ministry of Health has approved BeiGene’s Brukinsa (zanubrutinib) to treat patients with relapsed or refractory mantle cell lymphoma (MCL).

Brukinsa is approved in nine countries to treat mantle cell lymphoma. Credit: Gabriel Caponetti /  commons.wikimedia.org.